Zhejiang Hisun Group Co., Ltd., one of the 520 national key enterprises, is the country’s largest antibiotic and anti-tumor drug production base and a major chemical API production and export base, with total assets of 2.5 billion yuan and an area of ??900,000 square meters. , with nearly 2,000 employees. The core enterprise, Zhejiang Hisun Pharmaceutical Co., Ltd., is currently the only national high-tech enterprise in Taizhou City and the first listed company to issue A shares as a high-tech enterprise. Zhejiang Hisun Group Co., Ltd. is a nationally designated production base for antibiotics and anti-tumor drugs. It is also a key backbone enterprise of chemical raw materials and an export-earning enterprise in Zhejiang Province. In 1996, the company was recognized by the National Science and Technology Commission as a key high-tech enterprise of the National Torch Plan. In 1998 It was listed among the first batch of "Technological Innovation Pilot Enterprises" in Zhejiang Province in 2007, and was listed among the 520 national key enterprises nationwide by the State Council in 1999.
The company is located in Taizhou City, a coastal port city in central Zhejiang. It faces the sea to the east and has a pleasant climate. At present, the company’s total assets have reached 700 million yuan. The group has jurisdiction over Zhejiang Hisun Pharmaceutical Co., Ltd., Zhejiang Hisun Chemical Industry Co., Ltd., Zhejiang Jiangnan Pharmaceutical Factory, Jiaojiang Thermal Power Co., Ltd. and other holding subsidiaries achieved sales revenue of 400 to 800 million yuan in 1999, profits and taxes of 94.1 million yuan, and per capita annual income of 18,000 yuan. Zhejiang Hisun Pharmaceutical Co., Ltd., the company's core enterprise, mainly produces more than 40 kinds of drugs in four series: anti-tumor, anti-infection, anti-parasitic and cardiovascular. Hisun Pharmaceutical ensures product quality with scientific management, advanced technology, and first-class equipment. It has become the first pharmaceutical company in Zhejiang Province to pass the IS09002 quality assurance system certification. The company has obtained the French ATN management system model recognition certificate. At present, the company has 8 products to fill the domestic gaps, 4 national-level new products, 5 products including doxorubicin, ivermectin, daunorubicin, etc. have passed the US FDA certification (Food and Drug Administration) product 75 or more It is exported to more than 30 countries and regions including Europe and the United States. Hisun Pharmaceutical was listed on the Shanghai Stock Exchange on July 25, 2000 as a national high-tech enterprise.